Denmark

Please select...

Disclosure of payments made to HCPs in Denmark

In recent years GSK has challenged the traditional commercial model of pharmaceutical companies with industry-leading improvements to how we do business. Our improvements aim to meet society’s growing expectation for organisations and individuals to act with transparency. This includes relationships between our industry and healthcare professionals (HCPs) or healthcare organisations (HCOs) so all of these interactions are conducted with integrity and transparency.

In Denmark, GSK strictly complies with the requirements of Danish national law (decree number L94/2013-14).These disclosures were implemented in Denmark in November 2014 and are published and publicly available on the transparency website of the Danish Medicines Agency / Laegemiddelstyrelsen.

Across Europe,we fully support the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations.

Under the EFPIA code, and by 30 June 2016, EFPIA member companies across Europe, including GSK, have pledged to disclose transfers of value made in 2015 to HCPs and HCOs in connection with prescription medicines on an individual-named basis (aggregate by exception only). The EFPIA disclosures include, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings, and grants to HCOs. Transfers of value to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.

EFPIA has assessed the Danish legislation on disclosure to meet the requirements for transparency, and Denmark has accordingly been exempted by EFPIA from implementing the EFPIA Disclosure Code given the disclosures already through the Danish Medicines Agency / Laegemiddelstyrelsen.

Legislation in Denmark requires HCPs to self-disclose:

  • Any engagement with a pharmaceutical company including zero payment engagements
  • All R&D engagements by named disclosure
  • Congress sponsorships (no amount disclosure)

Our disclosures in Denmark via Danish Medicines Agency / Laegemiddelstyrelsen include all transfers of value made by GSK to individual HCPs. Any payments to healthcare organisations (HCOs) and hospitals in Denmark are disclosed on the Grants & Donations section on the GSK Denmark corporate website.

However, as of 1 January 2016, across all of its business worldwide, and including in Denmark, GSK ended all payments to external HCPs to speak about our prescription medicines or vaccines to audiences who can prescribe or can influence prescribing.  

Disclosures by GSK Denmark of transfers of value to HCPs and HCPs for speaking engagements to audiences that can prescribe or influence prescribing therefore relate to 2015 and earlier, before GSK ended all such speaker payments on 1 January, 2016.

The global changes by GSK to end speaker payments go further than the current industry codes and therefore further than other companies in the industry. We continue, at the same time, to work with HCPs in Denmark and globally for non-promotional activities such as clinical research or support to medical education.

We believe the disclosures made in Denmark under the law, and in other European countries in compliance with both applicable national laws and the EFPIA disclosure code, will help to create a better understanding of how the pharmaceutical industry works with HCP community and HCOs.

Given the measures GSK has put in place we seek to increase society’s confidence in, and understanding of, how and why we work with healthcare professions for the sustainable improvement of healthcare and in the best interests of patients. More information on our approach to the EFPIA code, how we are leading improvements to industry practices, and the importance of our partnerships with HCPs and HCOs can be found below, and is set out in greater detail. 

Media inquiries: Please contact Head of Communications Henrik Kastoft, mobile +45 2469 9287 or e-mail henrik.xkastoft@gsk.com

GSK’s approach to HCP payments and implementing the EFPIA Code across Europe

By 1 January 2016, we ended in all parts of the world, including in Denmark, any payment of HCPs congress participation and any payments to external HCPs to speak about our prescription medicines and vaccines although payments before this date are reflected in our disclosures for 2015 and in Denmark our previously published disclosures via Danish Medicines Agency / Laegemiddelstyrelsen.

We will continue to work with HCPs for non-promotional activities including conducting clinical research and seeking advice on clinical relevance and appropriate communication of the results of our research, as well as identifying new research areas. We believe that these interactions are an essential part of how we ensure medicines we develop meet patients’ needs.

Find out how disclosing information on payments to doctors has already had positive effects in Europe.

We also continue to work towards publishing global figures at an aggregate level for payments to HCPs, for activities such as advisory services and clinical research. In many countries outside Europe we already publish payments to HCPs – for example, in Australia, Japan and the US. Find out more about our payments to HCPs in the USA, Europe and the rest of the world on the other pages within this section. We will continue to support and work towards increased transparency in other countries as industry associations and/or governments establish specific guidelines for disclosure.

New below 

Disclosure of payments made to HCPs in Denmark

In recent years GSK has challenged the traditional commercial model of pharmaceutical companies with industry-leading improvements to how we do business. Our improvements aim to meet society’s growing expectation for organisations and individuals to act with transparency. This includes relationships between our industry and healthcare professionals (HCPs) or healthcare organisations (HCOs) so all of these interactions are conducted with integrity and transparency.

In Denmark, GSK strictly complies with the requirements of Danish national law (decree number L94/2013-14).These disclosures were implemented in Denmark in November 2014 and are published and publicly available on the transparency website of the Danish Medicines Agency / Laegemiddelstyrelsen.

EFPIA has assessed the Danish legislation on disclosure to meet the requirements for transparency, and Denmark has accordingly been exempted by EFPIA from implementing the EFPIA Disclosure Code given the disclosures already through the Danish Medicines Agency / Laegemiddelstyrelsen.

Nevertheless, across Europe we fully support the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations.

Under the EFPIA Code, the first disclosures – of payments made during 2015 – were made by 30 June 2016: these were disclosed transfers of value made in 2015 to HCPs and HCOs in connection with prescription medicines on an individual-named basis (aggregate by exception only). We are following the same process for disclosures of 2016 data of which all disclosures must be made by 30 June 2017.

Collaboration with HCPs and HCOs continues to be important. GSK collaborates with HCPs and HCOs for non-promotional activities such as clinical research. We have also introduced new ways of delivering information to HCPs, introducing digital and real-time applications to improve delivery of medical information.

Legislation in Denmark requires HCPs to self-disclose:

  • Any engagement with a pharmaceutical company including zero payment engagements
  • All R&D engagements by named disclosure
  • Congress sponsorships (no amount disclosure)

Our disclosures in Denmark via Danish Medicines Agency / Laegemiddelstyrelsen include all transfers of value made by GSK to individual HCPs. Any payments to healthcare organisations (HCOs) and hospitals in Denmark are disclosed on the Grants & Donations section on the GSK Denmark corporate website.

However, as of 1 January 2016, across all of its business worldwide, and including in Denmark, GSK ended all payments to external HCPs to speak about our prescription medicines or vaccines to audiences who can prescribe or can influence prescribing.  

Disclosures by GSK Denmark of transfers of value to HCPs and HCPs for speaking engagements to audiences that can prescribe or influence prescribing therefore relate to 2015 and earlier, before GSK ended all such speaker payments on 1 January, 2016.

The global changes by GSK to end speaker payments go further than the current industry codes and therefore further than other companies in the industry. We continue, at the same time, to work with HCPs in Denmark and globally for non-promotional activities such as clinical research or support to medical education.

We believe the disclosures made in Denmark under the law, and in other European countries in compliance with both applicable national laws and the EFPIA disclosure code, will help to create a better understanding of how the pharmaceutical industry works with HCP community and HCOs.

Given the measures GSK has put in place we seek to increase society’s confidence in, and understanding of, how and why we work with healthcare professions for the sustainable improvement of healthcare and in the best interests of patients. More information on our approach to the EFPIA code, how we are leading improvements to industry practices, and the importance of our partnerships with HCPs and HCOs can be found below, and is set out in greater detail.

Media inquiries: Please contact Head of Communications Nina Henriksen, mobile +45 2469 9294 or e-mail nina.x.henriksen@gsk.com

GSK’s approach to HCP payments and implementing the EFPIA Code across Europe

Since 1 January 2016, we ended in all parts of the world, including in Denmark, any payment of HCPs congress participation and any payments to external HCPs to speak about our prescription medicines and vaccines although payments before this date are reflected in our disclosures for 2015 and in Denmark our previously published disclosures via Danish Medicines Agency / Laegemiddelstyrelsen.

We will continue to work with HCPs for non-promotional activities including conducting clinical research and seeking advice on clinical relevance and appropriate communication of the results of our research, as well as identifying new research areas. We believe that these interactions are an essential part of how we ensure medicines we develop meet patients’ needs.

Find out how disclosing information on payments to doctors has already had positive effects in Europe.

We also continue to work towards publishing global figures at an aggregate level for payments to HCPs, for activities such as advisory services and clinical research. In many countries outside Europe we already publish payments to HCPs – for example, in Australia, Japan and the US. Find out more about our payments to HCPs in the USA, Europe and the rest of the world on the other pages within this section. We will continue to support and work towards increased transparency in other countries as industry associations and/or governments establish specific guidelines for disclosure.

Offentliggørelse af samarbejde med sundhedspersoner i Danmark

I de senere år har GSK udfordret den gængse model for industriens samarbejde med sundhedspersoner og sat helt nye standarder i branchen. Reformerne har som mål at imødekomme samfundets forventninger om at organisationer og enkeltpersoner er transparente i deres arbejde. Det gælder således også vores samarbejde med sundhedspersoner, hospitaler og patientforeninger, som altid skal bygge på integritet og gennemsigtighed.

I Danmark lever GSK op til forpligtelserne i lovgivningen (lægeloven) og de ændringer, som blev indført med lovforslag L94/2013-14. Heraf fremgår, at offentliggørelse af sundhedspersoners samarbejde med industrien skal ske på Lægemiddelstyrelsens hjemmeside. De nye regler har været gældende siden november 2014.

EFPIA har evalueret den danske lovgivning om offentliggørelse for at imødekomme kravet om gennemsigtighed. På baggrund af de eksisterende regler om offentliggørelser under Lægemiddelstyrelsen, er Danmark følgelig blevet undtaget fra at implementere EFPIAs regelsæt om offentliggørelse.

Ikke desto mindre støtter GSK fuldt og helt European Federation of Pharmaceutical Industries and Associations (EFPIA) regelsæt for offentliggørelse af pengebløb/værdier overført fra medicinalvirksomhed til sundhedspersoner og organisationer.

I henhold til EFPIA-regelsættet blev de første offentliggørelser – af honorarer gennemført i 2015 – gennemført inden d. 30. juni 2016. Det gælder offentliggjorte værdioverførsler, der blev gennemført i 2015 til sundhedspersoner og foreninger i forbindelse med receptpligtig medicin, og er sket på enkeltperson/organisation og med navns nævnelse. Den samme procedure vil blive fulgt i 2016. Alle offentliggørelser skal ske inden d. 30 juni 2017.

Samarbejde med sundhedspersonale og organisationer er fortsat af stor betydning. GSK samarbejder med sundhedspersonale og organisationer om ikke-kommercielle aktiviteter såsom klinisk forskning. Vi har også indført nye måder at overlevere information til sundhedspersonale, herunder nye digitale og ”real-time” applikationer, for at fremme leveringen af medicinsk information. 

I henhold til den nationale lovgivning i Danmark skal sundhedspersoner (læger, tandlæger og apotekere) offentliggøre:

  • Samarbejde med lægemiddelvirksomheder – herunder samarbejde som ikke bliver aflønnet
  • Forskningssamarbejde
  • Sponsorat af kongres-deltagelse (dog ikke beløbsstørrelse)

Offentliggørelsen via Lægemiddelstyrelsens hjemmeside omfatter alle pengebeløb/værdier overført fra GSK til sundhedspersoner. Alle sponsorater til patientforeninger og hospitaler fremgår af GSKs danske hjemmeside under Grants & Donations.

Siden 1. januar 2016 har GSK i Danmark og i resten af vores virksomhed verden over stoppet direkte økonomisk støtte af lægers deltagelse på kongresser og stoppet udbetaling af honorar til sundhedspersoner, der overfor et publikum, som har ret til at udskrive medicin eller kan påvirke udskrivning af medicin, holder foredrag på vores vegne om vores lægemidler, vacciner eller terapeutiske fokusområder.  

Offentliggørelsen af honorar til sundhedspersoner for at have holdt et foredrag på et GSK-møde rettet mod andre sundhedspersoner, relaterer sig med andre ord til arrangementer afholdt før 1. januar 2016.

GSKs globale regler om at stoppe betaling af honorar til foredragsholdere er mere vidtgående end industriens egne regler, og dermed går GSK et skridt længere end andre medicinalselskaber.

Vi fortsætter ikke-kommercielle samarbejder med læger og sundhedspersoner i Danmark (eksempelvis klinisk forskning og efteruddannelse).

I GSK er vi af den opfattelse, at den danske lovgivning om offentliggørelse af samarbejdet mellem lægemiddelvirksomheder og sundhedspersoner i lighed med andre landes nationale lovgivning og EFPIAs regelsæt vil øge gennemsigtigheden og forståelsen for samarbejdet.

Med GSKs regler for honorar og kongresdeltagelse håber vi at kunne styrke samfundets tillid til og forståelse for, hvordan og hvorfor vi samarbejder med sundhedspersoner – et samarbejde, der i patientens interesse styrker øget sundhed. Yderligere information om vores holdning til EFPIAs regelsæt, GSKs egne regler og vigtigheden af vores samarbejde med sundhedspersoner og organisationer, finder du her.

Spørgsmål fra medier kan rettes til: Kommunikationschef Nina Henriksen, mobil +45 24 69 92 94 eller e-mail: nina.x.henriksen@gsk.com

GSKs holdning til offentliggørelse af samarbejde og implementering af EFPIA regelsættet i Europa

  1. januar 2016 indførte GSK i alle dele af verden et stop for direkte betaling af sundhedspersoners deltagelse på kongresser og et stop for honorarer til sundhedspersoner, som på vores vegne taler om GSKs lægemidler og vacciner. Offentliggørelsen, på Lægemiddelstyrelsen hjemmeside vedrører altså betalinger inden denne dato.

GSK vil fortsat samarbejde med  og kan honorere sundhedsfaglige eksperter for ikke-kommercielle projekter, herunder klinisk forskning, rådgivning om klinisk relevans af nye lægemidler/vacciner samt offentliggørelse af resultater af vores forskning, herunder at identificere nye behandlinger. Vi tror på, at disse forholdsregler er en væsentlig del af udviklingen af ny medicin, der kommer patienter til gavn.

Her kan du læse mere om, at GSK i Holland, Norge og i Danmark,  allerede nu oplever positive resultater af offentliggørelsen af samarbejdet.

Vi fortsætter desuden arbejdet frem mod globalt set at offentliggøre betalinger til sundhedspersoner for konsulentarbejde og klinisk forskning. I en række lande udenfor Europa har vi i en årrække offentliggjort samarbejdet med sundhedspersoner – det gælder eksempelvis i Australien, Japan og USA. Du kan læse mere om vores betalinger til sundhedspersoner i USA , Europa og resten af verden på de respektive sider.

GSK vil fortsat støtte og arbejde for øget åbenhed i andre lande efterhånden som brancheforeninger og regeringer etablerer retningslinjer for offentliggørelse.

Back to top